Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen BiotechnologyROCO:3176 -3.89%58 Median PS Value is NT$132.92 as of Jul. 15, 2026, which is 100% below its 10-year median of 0.24. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 278 Biotechnology companies, Medigen Biotechnology ranks better than 84.53% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Medigen Biotechnology's Median PS Value or its related term are showing as below:
ROCO:3176'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08 Med: 0.24 Max: 0.34
Current: 0.26
During the past 13 years, the highest Price to Median PS Value of Medigen Biotechnology was 0.34. The lowest was 0.08. And the median was 0.24.
ROCO:3176's Price-to-Median-PS-Value is ranked better than 84.53% of 278
companies
in the Biotechnology industry
Industry Median: 0.635
vs ROCO:3176: 0.26
Medigen Biotechnology (ROCO:3176) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Medigen Biotechnology's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
34.60
/
132.92
=
0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology Median PS Value Related Terms
Medigen Biotechnology Median PS Value Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 11.6935.
Medigen Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$11.367.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Median PS Value of NT$132.92 as of Jul. 15, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Medigen Biotechnology and its competitors. This is 55283% above median its historical median of 0.24. Over the past decade, Medigen Biotechnology's Median PS Value has ranged from 0.08 to 0.34. According to the industry distribution chart, Medigen Biotechnology ranks #43 out of 278 companies in the Biotechnology industry, placing it in the top 15.5%.
Is Medigen Biotechnology's Median PS Value too high?
Medigen Biotechnology's current Median PS Value of NT$132.92 is 55283% above median its 10-year median of 0.24. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.34. Based on the distribution chart, Medigen Biotechnology ranks #43 out of 278 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #43 out of 278 companies for Median PS Value. This places Medigen Biotechnology in the top 16% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.64. Historically, Medigen Biotechnology's own Median PS Value has ranged from 0.08 to 0.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.64, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median Median PS Value is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current Median PS Value is NT$132.92, which is 55283% above median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$34.60 — trading 30.3% below its estimated fair value. The current Median PS Value is NT$132.92, which is 55283% above median its 10-year median of 0.24. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Median PS Value is NT$132.92 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$34.60 is trading 30.3% below its estimated GF Value™ of NT$49.63.
GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.
Key valuation signals for ROCO:3176:
Median PS Value: NT$132.92 (55283% above median its 10-year median of 0.24)
GF Value™: NT$49.63 vs. price of NT$34.60 (30.3% below fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
